A Phase II Randomized Clinical Trial to Study the Efficacy and Safety of MK-5172 in Combination With Ribavirin (RBV) in Subjects With Chronic Hepatitis C Virus Infection

Trial Profile

A Phase II Randomized Clinical Trial to Study the Efficacy and Safety of MK-5172 in Combination With Ribavirin (RBV) in Subjects With Chronic Hepatitis C Virus Infection

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Apr 2017

At a glance

  • Drugs Grazoprevir (Primary) ; Ribavirin (Primary)
  • Indications Hepatitis C
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms C-SPIRIT
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 13 Apr 2014 Final results presented at the 49th Annual Meeting of the European Association for the Study of the Liver.
    • 13 Apr 2014 Status changed from active, no longer recruiting to completed as reported at the 49th Annual Meeting of the European Association for the Study of the Liver.
    • 01 Oct 2013 Results will be presented at the 64th American Association for the Study of Liver Diseases Annual Meeting (AASLD) according to a Merck media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top